[go: up one dir, main page]

CN101351191A - 生物利用率改善的非诺贝特药物制剂 - Google Patents

生物利用率改善的非诺贝特药物制剂 Download PDF

Info

Publication number
CN101351191A
CN101351191A CNA2005800524449A CN200580052444A CN101351191A CN 101351191 A CN101351191 A CN 101351191A CN A2005800524449 A CNA2005800524449 A CN A2005800524449A CN 200580052444 A CN200580052444 A CN 200580052444A CN 101351191 A CN101351191 A CN 101351191A
Authority
CN
China
Prior art keywords
fenofibrate
solid oral
agent type
pharmaceutical composition
oral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800524449A
Other languages
English (en)
Chinese (zh)
Inventor
E·I·莱尔纳
V·罗森伯格
M·弗拉什纳巴拉克
A·德拉布金
N·莫尔达夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101351191A publication Critical patent/CN101351191A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800524449A 2005-12-28 2005-12-28 生物利用率改善的非诺贝特药物制剂 Pending CN101351191A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/047346 WO2007075171A1 (en) 2005-12-28 2005-12-28 Pharmaceutical formulations of fenofibrate having improved bioavailability

Publications (1)

Publication Number Publication Date
CN101351191A true CN101351191A (zh) 2009-01-21

Family

ID=36499668

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800524449A Pending CN101351191A (zh) 2005-12-28 2005-12-28 生物利用率改善的非诺贝特药物制剂

Country Status (7)

Country Link
JP (1) JP2009522258A (ja)
CN (1) CN101351191A (ja)
BR (1) BRPI0520821A2 (ja)
CA (1) CA2634094A1 (ja)
IL (1) IL192230A0 (ja)
MX (1) MX2008008589A (ja)
WO (1) WO2007075171A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112618511A (zh) * 2020-12-31 2021-04-09 辰欣药业股份有限公司 一种非诺贝特胶囊的处方组成及制备工艺

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029181A1 (en) * 2009-09-09 2011-03-17 Bernard Charles Sherman Choline fenofibrate delayed release compositions
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
ES2940686T3 (es) * 2013-03-14 2023-05-10 Nestle Sa Fabricación de formulaciones de cacahuete para la desensibilización oral
KR101850119B1 (ko) 2015-11-11 2018-04-20 제이투에이치바이오텍 (주) 생체이용률이 향상된 신규한 페노피브르산 전구약물
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
TWI293877B (en) * 2000-09-20 2008-03-01 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
JP2005531521A (ja) * 2002-03-26 2005-10-20 テバ ファーマシューティカル インダストリーズ リミティド ドラッグ微粒子
RU2343905C2 (ru) * 2003-10-10 2009-01-20 Лайфсайкл Фарма А/С Твердые дозированные формы, включающие фибрат и статин
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112618511A (zh) * 2020-12-31 2021-04-09 辰欣药业股份有限公司 一种非诺贝特胶囊的处方组成及制备工艺

Also Published As

Publication number Publication date
CA2634094A1 (en) 2007-07-05
IL192230A0 (en) 2008-12-29
MX2008008589A (es) 2009-02-25
JP2009522258A (ja) 2009-06-11
WO2007075171A1 (en) 2007-07-05
BRPI0520821A2 (pt) 2009-06-30

Similar Documents

Publication Publication Date Title
CN109078006B (zh) 一种帕布昔利布的药物制剂及其制备方法
US7923026B2 (en) Embedded micellar nanoparticles
KR101267782B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
TW202332423A (zh) 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US20090263479A1 (en) Formulations for poorly permeable active pharmaceutical ingredients
CN101516344A (zh) 包含尼罗替尼或其盐的药物组合物
KR100962447B1 (ko) 난용성 약물인 두타스테라이드의 자가유화 조성물과 이로부터 제조된 정제
US8663697B2 (en) Solid dispersion preparation
CN103393617B (zh) 非布司他片剂及其制备方法
CN101528224A (zh) 包含坎地沙坦西酯的药用组合物
US20070248682A1 (en) Solid preparation comprising enteric solid dispersion
CN101351191A (zh) 生物利用率改善的非诺贝特药物制剂
CN102188417A (zh) 决奈达隆药物组合物
WO2014167579A2 (en) Stable pharmaceutical compositions of tadalafil
CN102423485B (zh) 含有醋酸去氨加压素的口服组合物及其制备方法
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof
CN104248769B (zh) 一种鲁拉西酮药物组合物及其制备方法
US20070148233A1 (en) Pharmaceutical formulations of fenofibrate having improved bioavailability
CN105287412A (zh) 一种阿立哌唑分散片及其制备方法
JPH0776516A (ja) 難溶性薬物含有製剤の製造方法
CN107375225B (zh) 一种琥珀酸呋罗曲坦缓释制剂及其制备方法
TWI278316B (en) Highly absorptive solid preparation
US20240216347A1 (en) Bezuclastinib formulations
CN103356486A (zh) 一种非诺贝特普伐他汀钠复方制剂的制备方法
JP4993274B2 (ja) フェノフィブラート含有製剤組成物の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090121